Trial
NCT00603941
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Anaplastic Thyroid Cancer
Intervention
CS-7017
Why stopped
Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated dose could not be established
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-16